Positive clinical performance of MSPrecise

[MSUK]

DioGenix reports positive clinical performance of molecular diagnostic MSPrecise for Multiple Sclerosis

DioGenix, Inc. announced today new data supporting the clinical validation of MSPrecise®, its proprietary next-generation sequencing (NGS) assay for the identification of patients with multiple sclerosis (MS) at first clinical presentation. The prospective study met its primary endpoint by demonstrating the ability of MSPrecise to diagnose patients with MS. The test performed consistently with previous clinical studies, having a specificity of 82% while maintaining sensitivity comparable to what has been published for the current standard of care (p= .0027)...... Read More - http://www.ms-uk.org/genetics